Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.

Slides:

Advertisements

Similar presentations

IN CANCER MOLECULAR DETECTION. WHAT DO THEY DETECT? Specific proteins Expression of certain genes Mutations Epigenetic Changes.

Advertisements

EGFR mutation in Austrian patients with NSCLC: a retrospective study

Epidermal growth factor receptor (EGFR) mutations in NSCLC

Volume 206, Issue 3, Pages (March 2013)

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Figure 1. Correlation between estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression in primary breast tumors and synchronous axillary.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Figure 1. Microscopic findings and karyotyping

EGFR Mutations in Lung Adenocarcinomas

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Detection of Exon 12 Mutations in the JAK2 Gene

Figure 1. MORT gene silencing is early event in cancer

Structure and mutation spectrum of BRCA2

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

سرطان الثدي Breast Cancer

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

An Alternative Method for Screening EGFR Mutation Using RFLP in Non-small Cell Lung Cancer Patients Ichiro Kawada, MD, Kenzo Soejima, MD, PhD, Hideo.

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

BIOLOGY 12 Cancer.

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next- Generation.

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Detection of Exon 12 Mutations in the JAK2 Gene

Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients Carmelo Tibaldi, MD,

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations:

EGFR Mutations in Lung Adenocarcinomas

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Erratum Journal of Thoracic Oncology

First Case of A859T Epidermal Growth Factor Receptor Mutation Responding to Erlotinib Laureline Le Maignan, BM, Delphine Mirebeau-Prunier, MD, PhD, Laurent.

Chien-Wei Chen, MD, Chin-Wei Kuo, MD Journal of Thoracic Oncology

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Meiotic Microdeletion Breakpoints in the BRCA1 Gene Are Significantly Associated with Symmetric DNA-Sequence Elements Beatrice Schmucker, Michael Krawczak

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas Jun Fan, MD Journal of Thoracic.

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

A–c) Case 1, with epidermal growth factor receptor (EGFR) exon 21 mutations (V843I and L858R). a) Pedigree chart. a–c) Case 1, with epidermal growth factor.

Figure 5. Effect of insulin-like growth factor 1 (IGF-1) induced extracellular regulated protein kinases 1/2 (ERK1/2) activation and the signal-responsive.

Figure 1. Chloride channel-3 (CIC-3) expression in breast tumor tissues. (A) Chloride channels (ClC-1–7, CFTR) are expressed in human breast cancer tissues.

Figure 4. Effects of chloride channel-3 (ClC-3) knockdown on the expression of cell cycle-regulatory proteins. (A) Representative western blot images of.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Location of common clinically relevant mutations in EGFR

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21. (B) Case with 9.0% mutation frequency for the L861Q mutation in EGFR exon 21. (C) Case with 10% mutation frequency for exon 19 deletion, L747_P753>Q. The numbers on the Y axis represent relative fluorescence unit. EGFR=epidermal growth factor receptor; LOD=limit of detection. Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21. (B) Case with 9.0% mutation frequency for the L861Q mutation in EGFR exon 21. (C) Case with 10% mutation frequency for exon 19 deletion, L747_P753>Q. The numbers on the Y axis represent… J Breast Cancer. 2017 Jun;20(2):150-159. https://doi.org/10.4048/jbc.2017.20.2.150